sq-23377 and 3-3--dipropyl-2-2--thiadicarbocyanine

Morphine, a mu-opioid agonist, suppressed the Ca(2+)-dependent release of glutamate that was evoked by exposing cerebrocortical synaptosomes to the potassium channel blocker 4-aminopyridine. The presynaptic inhibition produced by morphine was concentration-dependent and blocked by the nonselective opioid receptor antagonist naloxone. As determined by examining the mechanism of mu-opioid receptor-mediated inhibition of glutamate release, morphine caused a significant reduction in 4-aminopyridine-evoked increase in the cytoplasmic free Ca(2+) concentration ([Ca(2+)](c)), but failed to alter both 4-aminopyridine-evoked depolarization of the synaptosomal plasma membrane potential and Ca(2+) ionophore (ionomycin)-induced glutamate release. In addition, morphine was not capable of producing further inhibition on 4AP-evoked glutamate release in synaptosomes pretreated with the cannabinoid CB(1) receptor agonist WIN 55212-2, which has been shown to depress glutamate release through a suppression of presynaptic voltage-dependent Ca(2+) channel activity. These data suggest that morphine exerts its inhibitory effect presynaptically, likely through the reduction of Ca(2+) influx into nerve terminals, and thereby inhibits the release of glutamate in the cerebral cortex. This may therefore indicate that mu-opioid receptor agonists have neuroprotective properties, especially in the excessive glutamate release that occurs under certain pathological conditions.

Topics: 4-Aminopyridine; Analgesics, Opioid; Animals; Benzothiazoles; Benzoxazines; Calcium; Calcium Channel Blockers; Carbocyanines; Cerebral Cortex; Dose-Response Relationship, Drug; Exocytosis; Fluorometry; Fura-2; Glutamic Acid; Ionomycin; Ionophores; Male; Membrane Potentials; Morphine; Morpholines; Naloxone; Naphthalenes; Narcotic Antagonists; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley; Synaptosomes